Sartans Global Market Report 2025

Sartans, also known as angiotensin II receptor blockers (ARBs), are medications commonly prescribed to manage high blood pressure (hypertension) and heart failure. They work by blocking the action of angiotensin II, a hormone that constricts blood vessels, thereby promoting vessel relaxation, lowering blood pressure, and improving circulation. Sartans help reduce the risk of strokes, kidney damage, and heart attacks in individuals with specific cardiovascular conditions.

A sarcoidosis drug refers to any pharmacological substance used to manage the abnormal immune activity and granuloma development associated with sarcoidosis - a systemic inflammatory disease that primarily affects the lungs and lymph nodes. These medications work to alleviate symptoms and prevent damage to organs.

The primary types of sarcoidosis drugs are targeted for conditions such as ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, and sarcoidosis of the spleen, bone marrow, and lungs. Ocular sarcoidosis refers specifically to inflammation in the eyes caused by the disease, marked by the formation of granulomas in ocular tissues. This can lead to symptoms like redness, pain, and potential vision loss. Treatment approaches include corticosteroids, immunosuppressants, antimalarial drugs, and tumor necrosis factor-alpha (TNF-alpha) inhibitors. These medications are used to treat organ involvement in the lungs, skin, heart, and nervous system, and they can be administered orally, intravenously, or topically. Key end users include hospitals, clinics, surgical centers, diagnostic centers, and other healthcare institutions.

The sarcoidosis drug market research report is one of a series of new reports that provides sarcoidosis drug market statistics, including the sarcoidosis drug industry's global market size, regional shares, competitors with the sarcoidosis drug market share, detailed sarcoidosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis drug market. This sarcoidosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sarcoidosis drug market size has grown strongly in recent years. It will grow from $7.43 billion in 2024 to $7.96 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be credited to increased investment in orphan drug development, expanded research and development efforts focused on granulomatous diseases, wider use of corticosteroids and immunosuppressants for symptom control, an expanding clinical pipeline of innovative sarcoidosis treatments, and a heightened emphasis on personalized and targeted therapeutic approaches.

The main types of sartans include valsartan, telmisartan, losartan, irbesartan, azilsartan, and olmesartan. Valsartan, an angiotensin II receptor blocker (ARB), lowers blood pressure and reduces heart strain by relaxing blood vessels. It is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Valsartan is used for several applications, including hypertension, cardiovascular diseases, kidney diseases, and more, and is employed by various end-users such as hospitals, diagnostic laboratories, and others.

The sartans market research report is one of a series of new reports that provides sartans market statistics, including the sartans industry global market size, regional shares, competitors with the sartans market share, detailed sartans market segments, market trends, and opportunities, and any further data you may need to thrive in the sartans industry. This sartans market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sartans market size has grown steadily in recent years. It will grow from $21.36 billion in 2024 to $22.39 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to factors such as the growing adoption of sedentary lifestyles, the increasing incidence of obesity, rising awareness about cardiovascular diseases, higher healthcare expenditure, and the rising demand for generic antihypertensive drugs.

The sartans market size is expected to see steady growth in the next few years. It will grow to $26.66 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The forecasted growth can be attributed to several factors, including a heightened focus on combination therapies, increased investments in pharmaceutical R&D, rising demand in emerging markets, expanded healthcare infrastructure, and the growing prevalence of lifestyle-related disorders. Key trends expected during this period include advancements in drug delivery technologies, the development of advanced manufacturing processes for APIs, the creation of fixed-dose combination drugs, innovations in personalized hypertension treatments, and the development of novel sartan derivatives.

The rising prevalence of hypertension is expected to drive the growth of the sartans market. Hypertension, a condition characterized by persistently high blood pressure, increases the risk of heart disease, stroke, and other serious health complications. The growing incidence of hypertension is largely linked to diets high in salt and processed foods, which can lead to fluid retention and added strain on the heart. Sartans help manage hypertension by blocking angiotensin II, a hormone that causes blood vessels to constrict. By relaxing and widening the blood vessels, sartans lower blood pressure and reduce the heart's workload. For example, in January 2024, the American Heart Association reported that high blood pressure was responsible for 131,454 deaths in 2022, an increase from 124,508 deaths in 2021. As a result, the rising prevalence of hypertension is driving the growth of the sartans market.

Leading companies in the sartans market are focusing on developing advanced products, such as tablet-form sartans, to improve treatment efficacy and patient adherence. These oral medications contain sartan drugs, which block the effects of angiotensin II, promoting blood vessel relaxation and lowering blood pressure. For example, in July 2024, Zydus Lifesciences, an India-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Valsartan Tablets USP (40 mg, 80 mg), marketed under the brand name Diovan. These tablets are prescribed to treat hypertension, heart failure, and to improve survival after a heart attack in adults, and are also suitable for pediatric patients aged one year and older.

In April 2025, Scienture Holdings, Inc., a U.S.-based manufacturer of sartans, partnered with Saptalis Pharmaceuticals to develop and distribute Arbli (losartan potassium oral suspension, 10 mg/mL). This collaboration includes warehousing and distribution agreements with strategic partners to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in the treatment of hypertension. Saptalis Pharmaceuticals is a U.S.-based pharmaceutical company.

Major players in the sartans market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

North America was the largest region in the sartans market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sartans report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sartans market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sartans market consists of sales of candesartan, eprosartan, and fimasartan. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.